login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
LAVA THERAPEUTICS NV (LVTX) Stock News
USA
- NASDAQ:LVTX -
NL0015000AG6
-
Common Stock
1.485
USD
+0.02 (+1.02%)
Last: 9/19/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
LVTX Latest News, Press Relases and Analysis
All
Press Releases
18 days ago - By: Benzinga
- Mentions:
CSBR
CAPR
TCRT
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
a month ago - By: LAVA Therapeutics N.V.
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: Halper Sadeh LLP
- Mentions:
SCS
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders
2 months ago - By: Benzinga
- Mentions:
INSP
IP
NVO
XYZ
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
a year ago - By: BusinessInsider
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
a year ago - By: InvestorPlace
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
a year ago - By: BusinessInsider
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
2 months ago - By: Brodsky & Smith LLC
- Mentions:
HLVX
SCS
RKDA
XOMA
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
2 months ago - By: Halper Sadeh LLC
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
2 months ago - By: XOMA Royalty Corporation; LAVA Therapeutics N.V.
- Mentions:
XOMA
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
2 years ago - By: BusinessInsider
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
4 months ago - By: LAVA Therapeutics N.V.
LAVA Reports First Quarter 2025 Financial Results, Provides Business Update
5 months ago - By: LAVA Therapeutics N.V.
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
6 months ago - By: LAVA Therapeutics N.V.
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
8 months ago - By: LAVA Therapeutics N.V.
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
10 months ago - By: LAVA Therapeutics N.V.
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
a year ago - By: LAVA Therapeutics N.V.
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
a year ago - By: LAVA Therapeutics N.V.
LAVA Reports Second Quarter 2024 Financial Results and Business Update
a year ago - By: LAVA Therapeutics N.V.
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
a year ago - By: LAVA Therapeutics N.V.
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
a year ago - By: LAVA Therapeutics N.V.
LAVA Announces Annual Meeting of Shareholders
a year ago - By: LAVA Therapeutics N.V.
LAVA Announces Annual Meeting of Shareholders
a year ago - By: LAVA Therapeutics N.V.
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
a year ago - By: InvestorPlace
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
a year ago - By: LAVA Therapeutics N.V.
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
a year ago - By: LAVA Therapeutics N.V.
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
a year ago - By: LAVA Therapeutics N.V.
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
2 years ago - By: InvestorPlace
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
2 years ago - By: LAVA Therapeutics N.V.
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
2 years ago - By: LAVA Therapeutics N.V.
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
2 years ago - By: LAVA Therapeutics N.V.
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
2 years ago - By: FN Media Group LLC
- Mentions:
ONCY
ONC.CA
OCEA
MRK
...
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Please enable JavaScript to continue using this application.